Last reviewed 2026-05-19 · How we verify

Part 1 ES002023

Elpiscience Biopharma, Ltd. · Phase 1 active Small molecule ✓ Verified May 2026

Part 1 ES002023 is a Small molecule drug developed by Elpiscience Biopharma, Ltd.. It is currently in Phase 1 development.

Here's a 2-sentence factual summary of Part 1 ES002023: Part 1 ES002023 is a first-in-human, dose-escalation study of ES002023, a small molecule, in patients with locally advanced or metastatic solid tumors. The study is part of a larger clinical trial (NCT05075564) conducted by Elpiscience Biopharma, Ltd.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Part 1 ES002023
Sponsor	Elpiscience Biopharma, Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part 1 ES002023 CI brief — competitive landscape report
Part 1 ES002023 updates RSS · CI watch RSS
Elpiscience Biopharma, Ltd. portfolio CI

Frequently asked questions about Part 1 ES002023

What is Part 1 ES002023?

Part 1 ES002023 is a Small molecule drug developed by Elpiscience Biopharma, Ltd..

Who makes Part 1 ES002023?

Part 1 ES002023 is developed by Elpiscience Biopharma, Ltd. (see full Elpiscience Biopharma, Ltd. pipeline at /company/elpiscience-biopharma-ltd).

What development phase is Part 1 ES002023 in?

Part 1 ES002023 is in Phase 1.

Manufacturer: Elpiscience Biopharma, Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing